arrow
H

Hedyeh Ebrahimi

Beth Israel Deaconess Medical Center
H指数:25
被引数:5.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

18 Prediction of Immune-Related Adverse Events (irAEs) with Hematologic Markers in Patients Receiving First-Line Immune Checkpoint Inhibitor (ICI)-Based Therapy in Metastatic Renal Cell Carcinoma (mRCC)

18 预测接受一线免疫检查点抑制剂(ICI)治疗的转移性肾细胞癌(mRCC)患者中,利用血液学标志物预测免疫相关不良事件(irAEs)

2026-09-020
OAAI
Clinical Predictors and Prognostic Significance of Pathologic Disease Upstaging at Radical Cystectomy in Patients with Muscle-Invasive Bladder Cancer

肌层浸润性膀胱癌患者根治性膀胱切除术中病理疾病升级的临床预测因素及预后意义

2025-10-090
OA
Efficacy and safety of antibody-drug conjugate combination therapy in advanced urothelial carcinoma

抗体药物偶联物联合疗法在晚期尿路上皮癌中的疗效与安全性

2025-10-070
OAAI
Clinical and Pathological Predictors for Occult Lymph Node Involvement in Patients With Clinical Node-Negative Bladder Cancer Undergoing Radical Cystectomy

临床和病理学预测因子:在接受根治性膀胱切除术的临床淋巴结阴性的膀胱癌患者中 occult 淋巴结受累的预测因子

2025-09-010
PRE
Eligibility Criteria in Advanced Urothelial Cancer Clinical Trials: An Assessment of Modernization and Inclusion

晚期尿路上皮癌临床试验的纳入标准:现代化与包容性的评估

2025-03-270
OAAI
Efficacy of Treatments After Lenvatinib in Patients with Advanced Renal Cell Carcinoma

晚期肾细胞癌患者接受乐伐替尼治疗后后续治疗的疗效

2024-12-070
PRE
Impact of Synchronous versus Metachronous Metastasis on Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with First-line Immune Checkpoint Inhibitor-based Combinations
2024-09-010
OAAI
Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

卡博替尼和nivolumab联合或不联合活细菌补充治疗转移性肾细胞癌: 一项随机1期试验

2024-06-285
OAAI
Prevalence of Dietary Modification and Supplement Use in Patients with Metastatic Renal Cell Carcinoma Receiving Systemic Therapy
2024-05-260
OAAI
Barriers to Clinical Trial Implementation Among Community Care Centers
2024-04-292
OAAI
Burden of Ischemic Heart Disease and Its Attributable Risk Factors in North Africa and the Middle East, 1990 to 2019: Results From the GBD Study 2019
2024-01-165
OAAI
Assessment of eligibility criteria in renal cell carcinoma trials evaluating systemic therapy
2023-09-011
OAAI
Genomic and Transcriptomic Predictors of Response from Stereotactic Body Radiation Therapy in Patients with Oligoprogressive Renal Cell Carcinoma

寡进展性肾细胞癌患者立体定向放射治疗反应的基因组和转录组学预测因子

2023-08-013
PRE
eLife's new model and its impact on science communication
2022-12-081
OA
Global, regional, and national burden of respiratory tract cancers and associated risk factors from 1990 to 2019 a systematic analysis for the Global Burden of Disease Study 2019

全球、区域和国家呼吸道癌症负担及相关危险因素1990年2019年全球疾病负担研究的系统分析2019

2021-09-01100
OAAI
Ways to increase equity, diversity and inclusion
2020-07-079
OA